{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Apyx Medical Corp.
Apyx Medical Corp. Hits New 52-Week High of $3.65, Up 109%
Apyx Medical Corp. has achieved a new 52-week high of USD 3.65, reflecting a significant increase over the past year. The company, with a market capitalization of USD 78 million, remains unprofitable and exhibits a high price-to-book ratio, indicating a premium valuation amidst its volatility in the pharmaceuticals and biotechnology sector.
Apyx Medical Corp. Hits New 52-Week High of $3.49
Apyx Medical Corp. has achieved a new 52-week high of USD 3.49, reflecting a significant increase in stock performance over the past year. With a market capitalization of USD 78 million, the company operates in a competitive pharmaceuticals and biotechnology sector, despite currently facing losses.
Apyx Medical Corp. Hits New 52-Week High of $3.47, Up 112.5%
Apyx Medical Corp. has achieved a new 52-week high of USD 3.47, reflecting a significant increase in stock performance over the past year. With a market capitalization of USD 78 million, the company operates in a competitive biotechnology sector, facing challenges but showing notable market momentum.
Apyx Medical Corp. Hits New 52-Week High of $3.22
Apyx Medical Corp. has achieved a new 52-week high of USD 3.22, reflecting an impressive increase in stock performance over the past year. With a market cap of USD 78 million, the company operates in a competitive biotechnology sector, though it currently faces challenges with negative return on equity.
Apyx Medical Corp. Hits New 52-Week High of $2.99
Apyx Medical Corp. has achieved a new 52-week high of USD 2.99, reflecting an 80.62% increase in stock price over the past year. With a market capitalization of USD 78 million, the company operates in a competitive sector, despite currently facing losses and a negative return on equity.
Is Apyx Medical Corp. technically bullish or bearish?
As of August 19, 2025, Apyx Medical Corp. shows a mildly bullish trend with strong daily moving averages, though caution is advised due to mixed indicators, and it has significantly outperformed the S&P 500 over the past year but underperformed over three and five years.
Is Apyx Medical Corp. technically bullish or bearish?
As of June 20, 2025, the trend is bullish with strong daily moving averages and a bullish weekly MACD, though caution is advised due to a bearish monthly RSI, while performance against the S&P 500 shows a significant 1-month return of 29.87%.
Who are in the management team of Apyx Medical Corp.?
As of March 2022, the management team of Apyx Medical Corp. includes Andrew Makrides (Independent Chairman), Charles Goodwin (CEO), John Andres (Independent Vice Chairman), Lawrence Waldman (Lead Independent Director), and several Independent Directors: Minnie Baylor-Henry, Michael Geraghty, and Craig Swandal. They oversee the company's strategic direction and operations.
What does Apyx Medical Corp. do?
Apyx Medical Corporation is a micro-cap company that designs and manufactures electrosurgical equipment in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $9 million and a net loss of $4 million.
How big is Apyx Medical Corp.?
As of Jun 18, Apyx Medical Corp. has a market capitalization of 66.52 million, with net sales of 47.29 million and a net profit of -20.14 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
